Hormonal contraceptives, stress, and the brain: The critical need for animal models
Source : https://www.sciencedirect.com/science/article/abs/pii/S0091302222000589
Hormonal contraceptives are among the most important health and economic developments in the 20thCentury, providing unprecedented reproductive control...
Conclusion: Identifying who will likely benefit from specific formulations of HCs and predicting who is likely at risk for adverse side effects will allow for more people to benefit from the economic and health benefits of HCs, with fewer people experiencing depression and other adverse mood-related side effects. To do this, we first need to...
Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection - BMC Women's Health
Source : https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-022-01940-6
Objective To explore the effect of 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) in patients with moderate and severe intrauterine...
Conclusion: our data suggested that 4 mg/day doses of estrogen may have the same effect in improving the menstrual condition, uterine cavity morphology, and reproductive ability compared to a higher dosage (6 mg/day estrogen and 8 mg/day). In addition, the placement of IUD in the uterine cavity during TCRA may cause IUD incarceration, and the...
General Approaches to Medical Management of Menstrual Suppression
Number 3 (Replaces Committee Opinion Number 668, August 2016) Committee on Clinical Consensus-Gynecology. This Clinical Consensus was developed by the American College of Obstetricians and Gynecologists' Committee on Clinical Consensus-Gynecology...
Conclusion: Expert opinion suggests that unscheduled bleeding can decrease with continued use; thus, a patient may be counseled to adhere to a method for 3–6 months before initiating medical management of breakthrough bleeding. However, if a patient finds the unscheduled bleeding unacceptable, several treatment options are available and should...
Conclusion: Ultimately, the findings highlighted how telehealth reimbursement parity policies alone were insufficient in addressing unmet need for contraceptive care.
BRCA mutation carriers' perception about benefits and risks associated with combined hormonal contraceptives use
Source : https://www.tandfonline.com/doi/full/10.1080/13625187.2022.2107199?src=
Abstract To evaluate the actual perceptions about combined hormonal contraceptives (CHCs) use in BRCA mutation carriers in comparison to women from the general population. This was a cross-sectional, observational study...
Conclusion: Investing time and effort in transmitting the correct key messages about oncological risk related to CHC use could potentially increase their use in BRCA mutation carriers.